Radioaerosol Pulmonary Deposition During Asthma Exacerbation Through Noninvasive Ventilation

Analysing the Effects of Coupling Nebulization to Noninvasive Ventilation Through Pulmonary Scintigraphy on the Radioaerosol Deposition During Asthma Exacerbation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01012050

Acronym

Enrollment

Registered

2009-11-11

Start date

2007-06-30

Completion date

2008-01-31

Last updated

2009-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, status asthmatics

Brief summary

Despite the physiologic and clinical effects provided by coupling nebulization with noninvasive ventilation in asthma exacerbation, there are few and controversial studies reported in the literature.

Detailed description

Reduced work of breathing, increased oxygenation and increased in expiratory peak flow (EPF) and forced expiratory volume in the first second (FEV1) are benefits of noninvasive ventilation (NV) in the treatment of asthma. Despite these clinical improvements attributed to NV during asthma exacerbations and the well-established effects of nebulization, there are few studies in the literature coupling both therapeutic resources. In addition to this, no studies on scintigraphic analysis of radioaerosol deposition coupled with NV in asthmatics have published. A previous study was published by our group, but involved healthy subjects.

Interventions

DEVICENV

Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)

OTHERNEB group

Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of moderate to severe asthma (FEV1 \< 60 % of predicted values) * Breathing rate \> 25 bpm * History of asthma for at least 1 year * Duration of current asthma attack of \< 7 days * Reversibility of FEV1 of at least ≤ 10% after the administration of bronchodilator drugs

Exclusion criteria

* Current smoker * Presence of cardiopulmonary disease (COPD, pneumonia, heart failure, myocardial infarction, pneumothorax) * Hyperthermia * Indication of intubation and invasive mechanical ventilation; * Hemodynamic instability (heart rate \> 150 bpm and systolic blood pressure \< 90 mmHg) * Cardiac arrhythmia * Changes in consciousness * Pregnancy * Contraindications to use NV

Design outcomes

Primary

Measure	Time frame
Cardiopulmonary characteristics	6 months

Secondary

Measure	Time frame
Radioaerosol pulmonary index, radioaerosol penetration index and pulmonary clearance.	6 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026